Thursday, September 29, 2022
News
NEWS HOME
»
PRN INDIA
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML
  SocialTwist Tell-a-Friend  
   

Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML

Entospletinib is currently being studied in the Phase 3 AGILITY registrational study, with data anticipated in second half of 2023

SAN MATEO, Calif. and SAN DIEGO, Aug. 16, 2022 /PRNewswire/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of diagnostic kits and services for oncology, today announced their agreement to develop a companion diagnostic (CDx) for use with Kronos Bio's investigational therapy, entospletinib. Entospletinib is Kronos Bio's lead clinical compound, currently in the ongoing Phase 3 registrational AGILITY study for the treatment of newly diagnosed NPM1-mutated acute myeloid leukemia (AML).

Invivoscribe & Kronos Partnership

The diagnostic will screen for the NPM1 mutation, which is present in approximately one-third of all patients with AML.

Over the past year, the two companies have worked together to develop and advance the diagnostic and prepare to submit the Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) at the same time as the submission of the entospletinib New Drug Application (NDA). The FDA requires the validation and approval of companion diagnostics used to select patients for treatment with a specific therapeutic agent.

The agreement builds on Invivoscribe's experience in developing and obtaining approval for diagnostics used for identification of patients with genetically mutated AML. Invivoscribe markets an FDA-approved CDx for FLT3-mutated AML.

"This companion diagnostic NPM1  mutation assay development work with Kronos Bio represents a significant milestone for our company," said Jeffrey Miller, Ph.D., chief scientific officer and chief executive officer of Invivoscribe. "Companion diagnostics play a key role in the development and approval of targeted drug therapies and these kinds of partnerships are critical to improving care for patients with cancer."

Kronos Bio's AGILITY trial is designed to assess the efficacy and safety of entospletinib in approximately 180 adults who have been newly diagnosed with NPM1-mutated AML. In the trial, patients are being randomized to receive entospletinib or placebo, in combination with standard induction and consolidation chemotherapy. The primary endpoint of the trial is measurable residual disease (MRD) negative complete response. Event-free survival (EFS) is a key secondary endpoint, and mature EFS data are anticipated to be used to support potential full approval.

"The development of the NPM1 mutation companion diagnostic is a critical step in our efforts to rapidly advance entospletinib," said Jorge DiMartino, M.D., Ph.D., chief medical officer and executive vice president of Clinical Development at Kronos Bio. "We are fortunate to benefit from Invivoscribe's prior experience in bringing to market companion diagnostics for patients with AML."

About Kronos Bio, Inc.

Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio's lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.

About Invivoscribe

Invivoscribe has focused on Improving Lives with Precision Diagnostics ® for more than 28 years, advancing the field of precision medicine by developing and selling standardized reagents, tests, and bioinformatics tools to more than 700 customers in 160 countries. Invivoscribe also has a significant impact on global health working with pharmaceutical companies to accelerate approvals of new drugs and treatments by supporting international clinical trials, developing, commercializing companion diagnostics, and providing expertise in both regulatory and laboratory services. With its proven ability to provide global access to distributable reagents, kits, and controls, as well as clinical trial services through our international clinical lab subsidiaries (LabPMM), Invivoscribe has demonstrated it is an ideal partner. For additional information please visit: www.invivoscribe.com or contact Invivoscribe at:  customerservice@invivoscribe.com.

Forward-Looking Statements

Statements in this press release that are not statements of historical fact are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release, in some cases, uses terms such as "anticipated," "designed," "following," "potential," "prepare," "will," "would" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding Kronos Bio's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential successful development of a companion diagnostic for use with entospletinib; the potential submission of a PMA for such companion diagnostic; the potential validation and regulatory approval of the companion diagnostic and its use with entospletinib following approval; the potential regulatory approval of entospletinib; the anticipated use of mature EFS data to support potential full approval of entospletinib; the anticipated timing for data from the AGILITY trial; the design of the AGILITY trial; and other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: whether Kronos Bio and Invivoscribe will be able to successfully develop a companion diagnostic for use with entospletinib on the timeline expected, or at all, including risks related to contractual performance and Kronos Bio's reliance on Invivoscribe to complete the validation of the companion diagnostic necessary to meet regulatory requirements; whether Kronos Bio will be able to initiate, progress or complete the AGILITY trial on the timeline expected, or at all, including due to risks inherent in the clinical development of novel therapeutics; risks related to Kronos Bio's limited experience as a company in conducting clinical trials; the risk that results of preclinical studies and early clinical trials are not necessarily predictive of future results; risks related to regulatory approval of novel therapeutic products and companion diagnostics, including the risk that lack of approval of a companion diagnostic (including the companion diagnostic being developed for use with entospletinib) may jeopardize approval of the novel therapeutic product (including entospletinib); and risks associated with the sufficiency of Kronos Bio's cash resources and need for additional capital. These and other risks are described in greater detail in Kronos Bio's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as filed with the SEC on August 4, 2022. Any forward-looking statements that are made in this press release speak only as of the date of this press release and are based on management's assumptions and estimates as of such date. Except as required by law, Kronos Bio assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Kronos Bio Contacts:
Marni Kottle
Kronos Bio
(650) 900-3450
mkottle@kronosbio.com

Investors:
Claudia Styslinger
Argot Partners
(212) 600-1902
kronosbio@argotpartners.com

Media:
Sheryl Seapy
Real Chemistry
(949) 903-4750
sseapy@realchemistry.com

Invivoscribe Contact:
Tony Lialin
Chief Commercial Officer, Invivoscribe
tlialin@invivoscribe.com

Logo - https://mma.prnewswire.com/media/1877742/Invivoscribe_Technologies_Inc_Kronos_Bio_Partnership.jpg

More News by PR Newswire India

LyondellBasell Postpones Restart of Berre, France Cracker until Next Year

SI GROUP EXPANDS LUBRICANT ADDITIVE PORTFOLIO WITH NEW AMINIC ANTIOXIDANT

KEREN AVIDAR NAMED INX GLOBAL GENERAL COUNSEL

Asian Hall of Fame Announces Induction 2022

ViewSonic Expands its Gaming Monitor Line with the New OMNI Series for Casual Gamers

Fibocom Launches New Generation of 5G Sub-6GHz and mmWave Module FX170(W) Series Based on Snapdragon X65 5G Modem-RF System at MWC Las Vegas 2022

Himalaya Wellness Company Partners with NIMHANS to Launch Project SURAKSHA

Dr. Giovanni De Micheli Honored with 2022 Phil Kaufman Award Presented by ESD Alliance and IEEE CEDA

Dynata's Global Consumer Trends survey: 53% of people are struggling to afford basic needs; 67% have reduced spending to combat inflation

BellSoft Releases Alpaquita Cloud Native Platform for Java Developers

LCOE-centered, 600W+ module drives global PV market with four key competencies

ABILITY DIABETES GLOBAL - A Landmark RCT in the field of PCI for patients with DM, completes Enrolment

Bitget Ranks As The Top Crypto Derivatives Exchange With 0 Trading Fees

CRMNEXT features in Gartner® Magic Quadrant 2022 as 'Visionary' in Sales Force Automation technology

IBIS STYLES ENTERS THE METAVERSE WITH 2022 'OPEN TO CREATORS' VIRTUAL ART GALLERY & CONTEST - FEATURING DIGITAL CREATORS FROM AROUND THE WORLD

Former CEO of Tricentis and renowned testing industry veteran, Sandeep Johri joins LambdaTest's board

Trina Solar Demonstrates Commitment to India, Showcases Cutting Edge N-Type Module at REI Expo 2022

Lifestyle's new festive campaign inspires one to groove in style

ZTE endorses Catalyzing Electrification Accord

FPT Industrial announces the acquisition of a minority stake in Blue Energy Motors

Moonfare Expands Foothold to India opening Digital Private Market Investing Platform to eligible investors

Ideanomics' subsidiary Energica to provide electric motorcycles for the upcoming G20 Bali summit

DBS Bank India collaborates with HDFC ERGO and Atradius to provide Trade Credit Insurance solution to Tata Metaliks

AFFINIS helps organizations ease compliance with the Structured Digital Database requirements of SEBI

Daiichi Sankyo joins Startup Creasphere's Program Powered by Plug and Play

Handheld releases new Nautiz X81: An ultra-rugged 5G Android 12 handheld with a familiar feel

The Mindful Foundation brings courses from Oxford Mindfulness Foundation to India

UST Recognized for Human Resources Excellence Across Nine Categories at the 2022 Brandon Hall Awards

ScentAir Continues its Sustainability Initiatives to Enhance Immersive Sensory Experience

Sweden spellbinds travellers with new chilling audio story

Edvoy launches 'Refer a friend' programme as thank you to student advocates

Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

WinWire Has Earned the Modernization of Web Applications to Microsoft Azure Advanced Specialization

UNIVERSAL MUSIC INDIA ACQUIRES MAJORITY STAKE IN TM VENTURES, A LEADING INDIAN MUSIC & ENTERTAINMENT COMPANY

M&M'S® Welcomes First New Character in a Decade

Global Business Leaders Say Hybrid Cloud is Critical to Modernization, Yet Security, Skills and Compliance Concerns Impede Success

GLOBAL STANDARD OF CARE SIGNIFICANTLY REDUCED DUE TO MENTAL HEALTH OF HEALTHCARE WORKERS

Vieworks to Showcase Industrial Cameras and Lenses at VISION 2022

Eviation's Alice Achieves Milestone with First Flight of All-Electric Aircraft

SAUDI ARABIA IS THE FASTEST GROWING TOURISM DESTINATION IN THE G20

Internet sensation Khaby Lame announced as QNB Group's Official FIFA World Cup Qatar 2022™ Brand Ambassador

GIGABYTE Launches Z790 Series Motherboards Supporting Dual-Generation Intel Processors

Deltek Research to Unveil Top Federal Contracting Opportunities for 2023

ViewSonic Unveils Industry-First Foldable 135" All-in-One LED Display Solution Kit

NEOM Tech & Digital Company steps into the future as 'Tonomus'

Global Fab Equipment Spending Forecast to Reach All-Time High of Nearly $100 Billion in 2022, SEMI Reports

Kohler India celebrates their 10th Year of Pecha Kucha in New Delhi, India

U.S. Soy Sustainability Assurance Protocol (SSAP) Certificates Can Now Be Transferred

CP KELCO PARTNERS WITH EXOPOLYMER TO BRING NEXT-GENERATION FUNCTIONAL BIOPOLYMERS TO MARKET

Old Mission Selects Solace to Support Rapid Growth of Business through Event-Driven Architecture

GIGABYTE Launches Four AMD X670 Motherboards for New Ryzen 7000 Processors

SRK Knowledge Foundation announces transformational partnership with The Global Network for Zero

LyondellBasell Announces Organizational Changes

HarperCollins India presents HAPPILY INSURED: Your Guide to Understanding Insurance and Leading a Stress-Free Life by Kapil Mehta

Hisense Unveils Its FIFA World Cup Qatar 2022™ TVC "Perfect Match" Ahead of Tournament

The 2022 4th "My China Story" International Short Video Competition Award Ceremony was held in Hangzhou, Zhejiang

Light up the festive season with 'Sale Dhamaka' on MSI's laptop range

GLOBAL LEADERS, EXPERTS, AND CULTURAL ICONS CONVENE AT THE MILKEN INSTITUTE ASIA SUMMIT TO CELEBRATE A TRANSFORMED WORLD

Bank of Baroda rolls out 'Khushiyon ka Tyohaar' as the Festive Season begins

XCMG New Port Machinery's High-end Intelligent Industrial Development Project Base Launches Production

NATIONAL INSTITUTE FOR HEALTH AND CARE RESEARCH CONDUCTS A GLOBAL ANNUAL MEETING TO ADDRESS RESEARCH IN SURGERY IN INDIA

DEAKIN UNIVERSITY HUBS to be set up in India at OP Jindal Global University, Symbiosis International University and Chitkara University

TargEDys and Inoliva announce they have entered a distribution partnership to bring Satylia® to Turkey

Top 50 Start-ups Bringing Innovation to the Global Homes and Buildings Industry

How Healthcare Organizations Can Enhance a Holistic Patient and Member View by Improving Insights from Data

Tata AIA Life Fortune Guarantee Pension gets a powerful upgrade

PDRL aims to certify 10,000+ candidates on AeroMegh Platform in the Drone Industry by the year 2024

DAZN ACCELERATES GLOBAL GROWTH MOMENTUM WITH ACQUISITION OF ELEVEN GROUP BUSINESSES

GoingZero Big Diwali Sale: Up to 40% Discount And Free Shipping On Zero Waste Products

Slow-fashion brand FREECULTR becomes the official merchandise partner for FIFA 2022™

Purple Quarter Facilitates HCAH's CTO, Ex-DealShare Techie Onboarded

Ghodawat Consumer awarded - Fastest growing FMCG Company of 2022

Cine Star Cricket League launched with television and entertainment industry's Divas

ELLE FANNING IS THE AMBASSADOR OF FAME, PACO RABANNE'S NEW FEMININE FRAGRANCE

Saudi Data, AI Authority (SDAIA) and Ministry of Energy Partner with IBM to Accelerate Sustainability Initiatives in Saudi Arabia Using AI

Unstoppable Women of Web3 Launches New Education Streams

PNAS Partners with Straive for Production Services

MOBILEUM convenes the region's leading telecom operators at WEMEET ASIA 2022

Bizverse has officially become a Meta long-term strategic partnership

STL divests IDS as a part of its ongoing portfolio realignment

Frost & Sullivan Honors Tampa Electric Company and Warren, Simpson & Butler County Water Districts with Itron Excellence in Resourcefulness Awards

Mindray Showcases Hematology Innovations and Academic Achievements to the World at ISLH 2022

Deepak Chopra & Seva.Love Announce "ChopraVerse: House of Enlightenment," the Metaverse for Wellbeing in Collaboration with Utopia

MSC TO DEVELOP AIR CARGO SOLUTION IN RESPONSE TO MARKET DEMAND

Harpercollins is proud to announce the upcoming release of The Anarchist Cookbook: A Toolkit to Protest and Peaceful Resistance by Aakar Patel Illustrations by PenPencilDraw

Saudi Arabia launches Nusuk, an integrated digital platform, to facilitate pilgrim journeys for visitors from around the world

MEIL's wholly owned subsidiary MeghaGas, now MCGDPL, to execute City Gas Distribution

Yabx emerges as a leader in digital lending platforms at the top Global Fintech Awards

FII Institute reveals the world's top priority is the rising cost of living

All about IBSAT - One of the Top MBA Entrance Exams in India

MAPIC India 2022 honors India's most admired retail and tech innovators at the MAPIC India Retail Awards

Hasiru Dala Innovations joins forces with Satma CE to give immutable waste traceability from collection to final product made from waste

Bank of Baroda launches Baroda Tiranga Deposits

Alicon Castalloy Limited wins large, multi-year order from Jaguar Land Rover for eMobility Platform

mCaffeine's Biggest Body Care Launch Gets an Overwhelming Response from the Audience: 1 Consumer Subscribed Every 3 Seconds for the Launch

On World Lung Day, Alkem Laboratories pledge to spread awareness about lung diseases through its initiative 'The Healthy Lungs'

LONGi is to showcase its award-winning Hi-MO 5 Series at the Renewable Energy India Expo 2022, unveiling its new Hydrogen Business exclusively for Indian customers

LEXUS INDIA ANNOUNCES MENTORS FOR THE LEXUS DESIGN AWARD INDIA 2023

Mane Kancor CEO Geemon Korah hailed as one of the best CEO's in India

SVKM's NMIMS signs an MoU with HTWG Konstanz, Germany, for short study and research

Top HR Chiefs from TTK Prestige, Silicon Labs, Virtusa, Bureau Veritas at Woxsen's Global HR Leadership Conclave 2022

Mastercard expands decades-long football legacy through GUINNESS WORLD RECORDS™ title with Luis Figo

Soroco and Whatfix Announce Strategic Partnership

ElevenEs produces a prototype of the largest LFP battery cell in Europe

SHEIN CELEBRATED "ROCK THE RUNWAY: SHEIN FOR ALL", ITS FW22 FASHION SHOW

Huawei Hosts the 9th Global Rail Summit in Berlin

Campus With A Conscience hosts a-week long SDG festival

Woxsen University spearheading the internationalisation of higher education in the region through brand new initiatives

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Uttarakhand CM congratulates Lt Gen Anil...
WBSSC scam: Partha, Arpita's judicial cu...
Sacrosanct duty of husband to maintain w...
Prohibition raid leaves Bihar police sta...
Mumbai: Lata Mangeshkar music college la...
Defence Minister visits frontline areas ...
More...    
 
 Top Stories
EAM Jaishankar assures US administr... 
Arrest warrant issued against produ... 
Delhi HC dismisses plea of Facebook... 
Afghan women face social, economic ... 
Delhi Police arrests shooters of Go... 
India strives for relationship buil... 
Mamata Banerjee plays 'dhak' at Dur... 
Pak: Rana Sanaullah-led high level ...